Libtayo
E579610
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Libtayo canonical | 1 |
| cemiplimab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6251174 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Libtayo Context triple: [Regeneron Pharmaceuticals, notableProduct, Libtayo]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Tagrisso
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Libtayo Target entity description: Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Tagrisso
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
immunotherapy drug
ⓘ
monoclonal antibody ⓘ prescription medicine ⓘ |
| bindsTo | PD-1 receptor on T cells ⓘ |
| hasAdverseEffect |
diarrhea
ⓘ
endocrinopathies ⓘ fatigue ⓘ immune-related colitis ⓘ immune-related hepatitis ⓘ immune-related pneumonitis ⓘ rash ⓘ |
| hasATCClass | L01FF ⓘ |
| hasDrugClass |
PD-1 inhibitor
ⓘ
immune checkpoint inhibitor ⓘ |
| hasForm | concentrate for solution for infusion ⓘ |
| hasGenericName | cemiplimab ⓘ |
| hasMechanismOfAction |
blocks interaction between PD-1 and its ligands
ⓘ
enhances T-cell mediated immune response against tumors ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasPharmacologicalEffect |
antineoplastic effect
ⓘ
immunomodulating effect ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasTherapeuticArea |
dermatologic oncology
ⓘ
oncology ⓘ thoracic oncology ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isIndicatedFor |
first-line treatment of certain non-small cell lung cancers
ⓘ
locally advanced basal cell carcinoma ⓘ locally advanced cutaneous squamous cell carcinoma ⓘ metastatic basal cell carcinoma ⓘ metastatic cutaneous squamous cell carcinoma ⓘ |
| isUsedFor |
advanced lung cancer
ⓘ
advanced skin cancer ⓘ basal cell carcinoma ⓘ cutaneous squamous cell carcinoma ⓘ non-small cell lung cancer ⓘ |
| isUsedIn | adult patients ⓘ |
| regulates | immune checkpoint signaling ⓘ |
| targets |
PD-1 pathway
ⓘ
programmed cell death protein 1 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Libtayo Description of subject: Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Libtayo